Brief: Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study
03/12/2025 12:57
Dec 3 (Reuters) - Pharvaris NV PHVS.O: PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTENTIAL OF DEUCRICTIBANT FOR ON-DEMAND TREATMENT OF HAE ATTACKS PHARVARIS NV - PRIMARY ENDPOINT MET WITH SYMPTOM RELIEF IN 1.28 HOURS PHARVARIS NV - ALL SECONDARY EFFICACY ENDPOINTS MET IN RAPIDE-3 STUDY PHARVARIS NV - DEUCRICTIBANT CONFIRMED TO HAVE WELL-TOLERATED SAFETY PROFILE PHARVARIS NV - TO SUBMIT NDA TO FDA IN FIRST HALF OF 2026 Source text: ID:nGNX36XB0D Further company coverage: PHVS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharvaris NV
See all newsSwitzerland's Pharvaris Q1 loss per share narrows
Brief: Pharvaris Announces Pricing Of $115 Million Underwritten Offering Of Ordinary Shares
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
U.S. STOCKS ON THE MOVE-Wendy's, Bristol Myers Squibb, Macy's